Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-Maintenance
2022-500537-84-01Phase 3Authorised
- Sponsor
- Abivax
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in autoimmune colitis (3 arms), sponsored by Abivax. Primary endpoints: Endoscopic improvement at Week 44, Symptomatic remission at Week 44 and 5 more. Planned start Aug 2023; status: authorised.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500537-84-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500537-84-01.